Aquestive Therapeutics Inc (AQST) Stock Price, Quote & News

Company Profile

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 908 941 1900

Website: www.aquestive.com

Address:

30 Technology Drive, Warren, United States

shawn45 Aug. 4 at 12:11 AM

$AQST Team, Make sure to block this @ae1213 scammer - always posting negative with Bearish trend.

0 · Reply

shawn45 Aug. 4 at 12:08 AM

$AQST Awesome to see this AQST stock is going up slowly - $4.30 trade could be around the corner with Only 7 days left for a big news!! Either with news or no news, this stock worth to have for longer term. $MU $DELL $AMZN $NVDA

1 · Reply

Jumpingfox Aug. 3 at 7:40 PM

$AQST Speaking on the Q1 earnings call, Aquestive's CEO told analysts: “Today, I am providing guidance that we currently expect to have our human factors data and potentially our pharmacokinetic data for Anaphylm available in time for our August earnings call. Now the completion of this data is dependent on the FDA providing responses to our human factors protocol on time and the responses being within expectations, including with respect to the scope and content of that feedback.”

0 · Reply

drose0527 Aug. 3 at 6:42 PM

$AQST would t be surprised if we get a run to 3.90 by end of day

1 · Reply

drose0527 Aug. 3 at 5:39 PM

$AQST Next target 5.42. That might be here quicker than most of you think

0 · Reply

111ggg Aug. 3 at 3:09 PM

$AQST I guess I am posting to myself this morning. Haha. I will take ten cents a day up to earnings.

1 · Reply

UnderLion16 Aug. 3 at 2:37 PM

$AQST https://www.linkedin.com/posts/anaphylaxis-aquestive-medicalaffairs-share-7486181892627648512-8tZ2/?utm_source=share&utm_medium=member_desktop&rcm=ACoAAEsd0XQB-kbKVWH1Winw4qDcCWoIeyftplo

0 · Reply

111ggg Aug. 3 at 2:04 PM

$AQST not helping that bio/pharma sectors are weak this morning. OMER is up nicely but that is all day trader action basedvon weekend news. I would expect it to go back to near Fri close. ZVRA at least up a few pennies. TVTX continues to consolidate as it needed to. It is a buy sub 50 IMO.

0 · Reply

NCpilot172 Aug. 3 at 1:25 PM

$AQST Don’t think for one second Caremark isn’t aware of Anaphylm https://www.cvshealth.com/news/pbm/four-drugs-to-watch-in-2026-that-could-reshape-treatment-options.html

0 · Reply

111ggg Aug. 3 at 1:09 PM

$AQST let the buying begin.

0 · Reply

Aquestive Therapeutics to Report Second Quarter 2026 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET

Jul 7, 2026, 7:00 AM EDT - 27 days ago

Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism

2026-06-26T20:25:27.000Z - 5 weeks ago

Aquestive Therapeutics files to sell 230,271 shares of common stock for holders

Jun 26, 2026, 8:00 AM EDT - 5 weeks ago

Aquestive Therapeutics Registration statement: Registration filing

Jun 10, 2026, 9:30 AM EDT - 7 weeks ago

Aquestive Therapeutics Transcript: AGM 2026

May 14, 2026, 8:00 AM EDT - 2 months ago

Aquestive Therapeutics Earnings Call Transcript: Q1 2026

May 14, 2026, 8:00 AM EDT - 2 months ago

Aquestive Therapeutics Earnings release: Q1 2026

May 14, 2026, 8:00 AM EDT - 2 months ago

Aquestive Therapeutics Quarterly report: Q1 2026

May 14, 2026, 8:00 AM EDT - 2 months ago

Aquestive Therapeutics Slides: Q1 2026

2026-05-13T20:36:49.000Z - 2 months ago

Aquestive Therapeutics reports Q1 EPS (7c), consensus (13c)

May 13, 2026, 4:01 PM EDT - 2 months ago

Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

May 12, 2026, 9:31 AM EDT - 2 months ago

Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree

May 6, 2026, 7:00 AM EDT - 3 months ago

Aquestive Therapeutics to Report First Quarter 2026 Financial Results and Recent Business Highlights on May 13 and Host Conference Call on May 14 at 8:00 a.m. ET

Apr 24, 2026, 8:00 AM EDT - 3 months ago

Aquestive Therapeutics Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 3 months ago

Aquestive Therapeutics Proxy statement: Proxy filing

2026-04-24T11:41:01.000Z - 3 months ago

Aquestive Therapeutics assumed with an Outperform at Oppenheimer

Apr 16, 2026, 9:00 AM EDT - 3 months ago

AQST Lawsuit Alleges Allegedly Concealed Anaphylm NDA Deficiencies - AQUESTIVE THERAPEUTICS, INC. Investors Face Losses Following Allegedly Concealed Anaphylm NDA Deficiencies: SueWallSt

2026-04-15T13:51:38.000Z - 3 months ago

Investor Sue Aquestive Therapeutics Over ‘Postage Stamp’ Anaphylaxis Treatment Claims

Apr 9, 2026, 8:23 AM EDT - 4 months ago

AQUESTIVE THERAPEUTICS, INC. (AQST) DEADLINE ALERT Bernstein Liebhard LLP Reminds Aquestive Therapeutics, Inc. Investors of Upcoming Deadline

2026-03-30T11:16:34.000Z - 4 months ago

Aquestive Therapeutics completes Type A meeting with FDA for Anaphylm NDA

2026-03-20T11:11:07.000Z - 4 months ago

Aquestive chief legal officer, chief compliance officer Lori Braender steps down

Mar 20, 2026, 7:00 AM EDT - 4 months ago

Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A.

Mar 12, 2026, 9:00 AM EDT - 5 months ago

AQST Lawsuit Alleges Analyst Slashed Price Target - AQUESTIVE THERAPEUTICS, INC. Investors Face Losses Following Analyst Slashed Price Target: SueWallSt

Mar 10, 2026, 8:25 AM EDT - 5 months ago

Aquestive Therapeutics Transcript: The Citizens Life Sciences Conference 2026

Mar 9, 2026, 4:01 PM EDT - 5 months ago

Aquestive Therapeutics Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4)

Mar 9, 2026, 10:40 AM EDT - 5 months ago

Aquestive Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 6, 2026, 2:01 PM EST - 5 months ago

AQUESTIVE THERAPEUTICS, INC. (AQST) INVESTOR ALERT Investors With Large Losses in Aquestive Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

2026-03-05T18:20:15.000Z - 5 months ago

Aquestive Therapeutics price target lowered to $9 from $12 at Alliance Global

Mar 5, 2026, 8:00 AM EST - 5 months ago

Aquestive Therapeutics Earnings Call Transcript: Q4 2025

Mar 5, 2026, 8:00 AM EST - 5 months ago

Aquestive Therapeutics Annual report: Q4 2025

Mar 5, 2026, 8:00 AM EST - 5 months ago

Aquestive Therapeutics Earnings release: Q4 2025

Mar 5, 2026, 8:00 AM EST - 5 months ago

Aquestive Therapeutics Slides: Q4 2025

2026-03-04T21:20:27.000Z - 5 months ago

Aquestive Therapeutics reports Q4 adjusted EPS (15c), consensus (12c)

2026-03-04T21:19:36.000Z - 5 months ago

Aquestive Therapeutics sees FY26 revenue $46M-$50M, consensus $47.52M

Mar 4, 2026, 4:01 PM EST - 5 months ago

Aquestive Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Feb 26, 2026, 12:00 PM EST - 5 months ago

Aquestive Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 25, 2026, 7:00 AM EST - 5 months ago

Aquestive Therapeutics to Participate in Upcoming March Investor Conferences

Feb 24, 2026, 7:00 AM EST - 5 months ago

Aquestive Therapeutics to Report Fourth Quarter 2025 Financial Results and Recent Business Highlights on March 4 and Host Conference Call on March 5 at 8:00 a.m. ET

2026-02-20T12:06:15.000Z - 5 months ago

Aquestive announces poster presentations on Anaphylm at AAAAI meeting

2026-02-18T12:11:06.000Z - 5 months ago

Aquestive Therapeutics appoints Greenhawt as Chief Medical Officer

2026-02-03T13:46:32.000Z - 6 months ago

Aquestive Therapeutics price target lowered to $6 from $8 at Lake Street

2026-02-02T19:05:09.000Z - 6 months ago

Alliance Global sees Aquestive’s Anaphylm CRL as fixable, reiterates Buy rating

2026-02-02T15:45:14.000Z - 6 months ago

Leerink sees ‘silver lining’ in Aquestive CRL given defined path to approval

2026-02-02T15:40:09.000Z - 6 months ago

Aquestive CRL from FDA ‘clearing event,’ says Oppenheimer

Feb 2, 2026, 8:00 AM EST - 6 months ago

Aquestive Therapeutics Transcript: Status update

Feb 2, 2026, 8:00 AM EST - 6 months ago

Aquestive Therapeutics Press release: Status update

Feb 2, 2026, 8:00 AM EST - 6 months ago

Aquestive Therapeutics Slides: Status update

2026-02-02T12:12:20.000Z - 6 months ago

Aquestive Therapeutics announces FDA issuance of CRL for Anaphylm

Feb 2, 2026, 7:10 AM EST - 6 months ago

US FDA declines to approve Aquestive's oral drug for allergic reactions

Feb 2, 2026, 7:00 AM EST - 6 months ago

Aquestive Therapeutics Announces FDA Issuance of Complete Response Letter for Anaphylm™

Jan 9, 2026, 7:00 AM EST - 7 months ago

Aquestive Therapeutics Announces Regulatory Development for Anaphylm™ (dibutepinephrine) Sublingual Film and Provides Business Update

Dec 4, 2025, 10:00 AM EST - 8 months ago

Aquestive Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 6, 2025, 8:00 AM EST - 9 months ago

Aquestive Therapeutics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 8:00 AM EST - 9 months ago

Aquestive Therapeutics Quarterly report: Q3 2025

Nov 6, 2025, 8:00 AM EST - 9 months ago

Aquestive Therapeutics Earnings release: Q3 2025

Nov 6, 2025, 8:00 AM EST - 9 months ago

Aquestive Therapeutics Slides: Q3 2025

Oct 27, 2025, 7:00 AM EDT - 10 months ago

Aquestive Therapeutics to Report Third Quarter 2025 Financial Results and Recent Business Highlights on November 5 and Host Conference Call on November 6 at 8:00 a.m. ET

Oct 8, 2025, 7:00 AM EDT - 10 months ago

Aquestive Therapeutics Broadens Patent Estate for Anaphylm™

Sep 28, 2025, 6:00 PM EDT - 11 months ago

Aquestive Therapeutics Slides: Corporate Presentation

Sep 8, 2025, 10:00 AM EDT - 11 months ago

Aquestive Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 8:00 AM EDT - 11 months ago

Aquestive Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Aug 14, 2025, 6:28 AM EDT - 1 year ago

Aquestive Therapeutics Announces Pricing of $85 Million Underwritten Offering of Common Stock

shawn45 Aug. 4 at 12:11 AM

$AQST Team, Make sure to block this @ae1213 scammer - always posting negative with Bearish trend.

0 · Reply

shawn45 Aug. 4 at 12:08 AM

1 · Reply

Jumpingfox Aug. 3 at 7:40 PM

0 · Reply

drose0527 Aug. 3 at 6:42 PM

$AQST would t be surprised if we get a run to 3.90 by end of day

1 · Reply

drose0527 Aug. 3 at 5:39 PM

$AQST Next target 5.42. That might be here quicker than most of you think

0 · Reply

111ggg Aug. 3 at 3:09 PM

$AQST I guess I am posting to myself this morning. Haha. I will take ten cents a day up to earnings.

1 · Reply

UnderLion16 Aug. 3 at 2:37 PM

$AQST https://www.linkedin.com/posts/anaphylaxis-aquestive-medicalaffairs-share-7486181892627648512-8tZ2/?utm_source=share&utm_medium=member_desktop&rcm=ACoAAEsd0XQB-kbKVWH1Winw4qDcCWoIeyftplo

0 · Reply

111ggg Aug. 3 at 2:04 PM

0 · Reply

NCpilot172 Aug. 3 at 1:25 PM

$AQST Don’t think for one second Caremark isn’t aware of Anaphylm https://www.cvshealth.com/news/pbm/four-drugs-to-watch-in-2026-that-could-reshape-treatment-options.html

0 · Reply

111ggg Aug. 3 at 1:09 PM

$AQST let the buying begin.

0 · Reply

Dragon_Algorithms Aug. 2 at 7:18 PM

$AQST Really think this see's a nice rally this year

0 · Reply

InnerVoice Aug. 2 at 9:56 AM

$AQST I think we are back around 4 by end of the coming week and we will see 4.30-4.50 during the following earnings week. Whether we fall back or go higher depends on the conference call. But we should see some movement. Being back up around 5 is not out of the question if we are on track with the studies and resubmission. Will know soon enough.

1 · Reply

kibli Aug. 1 at 11:07 PM

$AQST Libervant is not stalled internationally; its global commercialization is actively moving forward through regional partner Pharmanovia which has filed regulatory applications in nearly 20 countries outside the United States including the European Union, the United Kingdom, Switzerland, Norway, and the Middle East and North Africa (MENA). This means that commercial rollout depends on each nation's independent health authority greenlighting the drug. We should be hearing something in regards to these efforts soon.

0 · Reply

dl42 Aug. 1 at 7:10 PM

$AQST on Indeed

0 · Reply

kibli Aug. 1 at 5:38 PM

$AQST If I am not mistaken, to reach net profitability based on its current financial baseline, AQST needs to generate approximately $0.56 per share in additional net income, which equates to roughly $68.91 million in total profit. Just to say that with Libervant alone this coming Jan 2027, there is a chance that AQST will become profitable. The market will antedate that possibility and start building SP up.

0 · Reply

History101 Aug. 1 at 1:28 AM

$AQST AQST stock price way outperforming $SPRY % changes (+ or -) over several time periods per yahoo: AQST: 5d +0.4%, 1mo -11%, 6mo +25%, 1yr -3% SPRY: 5d -13%, 1mo -35%, 6mo -48%, 1yr -70%

1 · Reply

daken88 Aug. 1 at 12:02 AM

$AQST This is intriguing me also. AI seemed to (eventually) provide an explanation / reassurance, but not entirely sure I trust it to be correct...!

0 · Reply

Alex1710 Jul. 31 at 11:58 PM

$AQST I do not hold shares and I'm not here to bash but when I take a look at the 2025 financial results it shows $44,5 income which is not much for a company that has 6 products on market . My main concern is Selling, general and administrative = almost $80M , unless Anaphylm is a big commercial success I am very hesitating to become shareholders. Is there income projection for Anaphylm? Thanks and have a good weekend.

2 · Reply

Master_P_ Jul. 31 at 8:12 PM

$AQST This held up better than any other BIO on my watchlist

0 · Reply

ae1213 Jul. 31 at 5:33 PM

$AQST I am thinking what if someone has an adverse reaction while eating at a restaurant, what are they supposed to do, vimit out their food first and then apply Analfilm? What if they passed out, do others need to empty their mouth? I want to learn. I am not accumulating at these levels.. May be after August 12 at low 2$? I need to think about it …

2 · Reply

ToroLocou Jul. 31 at 4:22 PM

$AQST if you are not accumulating at these levels, you are doing it wrong.

0 · Reply

ae1213 Jul. 31 at 4:22 PM

$AQST beware of this shameless little pumper

1 · Reply

Market Cap	463.60M
Revenue (ttm)	44.55M
Net Income (ttm)	-83.78M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-188.06%
Debt to Equity Ratio	-0.74

Volume	2,381,300
Avg Vol	1,953,126
Day's Range	N/A - N/A
Shares Out	125.47M
Stochastic %K	45%
Beta	1.45
Analysts	Strong Sell
Price Target	$8.89